Fig. 2.
Antigen specific lysis of human melanoma cell lines by CTL clones. Cell lysis of the HLA-A2 positive melanoma cell line ESTDAB-007 without and with the HLA-specific antibody W6/32. In addition, unlabeled T2 cells either with or without the relevant peptide a MART-127–35, b Bcl-2208–217 were added to ESTDAB-007 cells at a ratio of inhibitor to target cells of 20:1. Moreover, cell lysis of the HLA-A2 negative melanoma cell line FM9. All 51Cr-release assays were performed in three E:T ratios